PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE
The present invention relates to amorphous solid dispersions (ASD) and solid pharmaceutical dosage forms for oral administration comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptaphane-74-c...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
30.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to amorphous solid dispersions (ASD) and solid pharmaceutical dosage forms for oral administration comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptaphane-74-carboxamide (active ingredient (I)), characterized in that the active ingredient (I) is immediately released from the amorphous solid dispersions (ASD) and the solid pharmaceutical dosage forms for oral administration, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders. |
---|---|
Bibliography: | Application Number: US202218549187 |